1-3 of 3
A. Van Hoof
Close
Sort by
Journal Articles

Palifermin Treatment in Patients Receiving High Dose Melphalan or BEAM Prior to Autologous Peripheral Blood Stem-Cell Transplantation.

Anne Sonet, MD, G. Bries, MD, N. Meulemans, MD, A. Van Hoof, MD, E. Steel, MD, M. André, MD, A. Ferrant, MD, N. Straetmans, MD, P. Zachée, MD, V. Robin, MD, H. Demuynck, MD, L. Noens, MD, A. Bosly, MD, M. Delforge, MD, D. Bron, MD
Journal: Blood
Blood (2006) 108 (11): 5241.
https://doi.org/10.1182/blood.V108.11.5241.5241
Published: 2006
Journal Articles

Assessing the Predictive Value of Plasma FLT3-L Levels for Hematologic Toxicity after Yttrium-90 Ibritumomab Tiuxetan ([ 90 Y]-Zevalin) Given as Consolidation in Patients with Advanced B-Cell Follicular NHL Responding to First Line Therapy.

F. Morschhauser, J. Radford, A. van Hoof, I. Kuss, A. Chlistalla, A. Hagenbeek
Journal: Blood
Blood (2005) 106 (11): 4795.
https://doi.org/10.1182/blood.V106.11.4795.4795
Published: 2005
Journal Articles

Follow-Up Results of a Prospective, Multicenter, Open-Label Study of Oral Fludarabine Phosphate in Patients with Previously Untreated B-CLL.

Jean-Francois Rossi, A. Van Hoof, K. De Boeck, S. A. Johnson, D. Bron, C. Foussard, T. A. Lister, M. H.H. Kramer, T. J. Littlewood, R. E. Marcus, E. Deconinck, O. Guibon, M. Montillo, S. M. Tollerfield
Journal: Blood
Blood (2005) 106 (11): 2128.
https://doi.org/10.1182/blood.V106.11.2128.2128
Published: 2005